EE05328B1 - Meetod amorfse atorvastatiini valmistamiseks - Google Patents

Meetod amorfse atorvastatiini valmistamiseks

Info

Publication number
EE05328B1
EE05328B1 EEP200200293A EEP200200293A EE05328B1 EE 05328 B1 EE05328 B1 EE 05328B1 EE P200200293 A EEP200200293 A EE P200200293A EE P200200293 A EEP200200293 A EE P200200293A EE 05328 B1 EE05328 B1 EE 05328B1
Authority
EE
Estonia
Prior art keywords
atorvastatin
solvent
preparation
type
amorphous form
Prior art date
Application number
EEP200200293A
Other languages
English (en)
Inventor
Pflaum Zlatko
Original Assignee
Lek Pharmaceutical And Chemical Company, D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company, D.D. filed Critical Lek Pharmaceutical And Chemical Company, D.D.
Publication of EE200200293A publication Critical patent/EE200200293A/et
Publication of EE05328B1 publication Critical patent/EE05328B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200200293A 1999-12-10 2000-12-05 Meetod amorfse atorvastatiini valmistamiseks EE05328B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9900271A SI20425A (sl) 1999-12-10 1999-12-10 Priprava amorfnega atorvastatina
PCT/IB2000/001797 WO2001042209A1 (en) 1999-12-10 2000-12-05 Process for the preparation of amorphous atorvastatin

Publications (2)

Publication Number Publication Date
EE200200293A EE200200293A (et) 2003-06-16
EE05328B1 true EE05328B1 (et) 2010-08-16

Family

ID=20432564

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200293A EE05328B1 (et) 1999-12-10 2000-12-05 Meetod amorfse atorvastatiini valmistamiseks

Country Status (22)

Country Link
US (2) US6613916B2 (et)
EP (1) EP1237864B1 (et)
JP (1) JP5087193B2 (et)
KR (1) KR100729689B1 (et)
AT (1) ATE270661T1 (et)
AU (1) AU776854B2 (et)
BG (1) BG65719B1 (et)
CA (1) CA2392025C (et)
CZ (1) CZ301627B6 (et)
DE (1) DE60012045T2 (et)
EE (1) EE05328B1 (et)
ES (1) ES2223615T3 (et)
HR (1) HRP20020482B1 (et)
PL (1) PL208226B1 (et)
PT (1) PT1237864E (et)
RS (1) RS50307B (et)
RU (1) RU2247113C2 (et)
SI (1) SI20425A (et)
SK (1) SK287032B6 (et)
TR (1) TR200402543T4 (et)
UA (1) UA71041C2 (et)
WO (1) WO2001042209A1 (et)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191236B (et) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (et) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
SK16002003A3 (sk) 2001-06-29 2004-12-01 Warner-Lambert Company Llc Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
WO2003018547A2 (en) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
HUP0500074A3 (en) * 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
AU2004228607B2 (en) 2003-04-11 2011-01-27 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
AU2004317570B2 (en) * 2004-03-17 2011-01-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
CA2562844A1 (en) * 2004-04-16 2005-10-27 Pfizer Products Inc. Process for forming amorphous atorvastatin calcium
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
KR20070054730A (ko) * 2004-10-18 2007-05-29 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법
CA2585836A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048888A1 (en) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Novel process for the preparation of amorphous atorvastatin calcium salt
WO2006048893A2 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited A process for synthesis of large particle size statin compounds
ES2263370B1 (es) * 2005-02-16 2007-12-01 Ercros Industrial, S.A. Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
WO2007057755A1 (en) 2005-11-21 2007-05-24 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
CN100429202C (zh) * 2006-06-30 2008-10-29 浙江新东港药业股份有限公司 一种无定形氟伐他汀钠的制备方法
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EP2132171A4 (en) * 2007-03-02 2010-11-17 Dong A Pharm Co Ltd NEW CRYSTALLINE FORMS OF PYRROLYLHEPTANIC ACID DERIVATIVES
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
PL2414130T5 (pl) * 2009-03-30 2019-10-31 Boegli Gravures Sa Sposób i urządzenie do strukturyzowania powierzchni obiektu litego z twardą powłoką pierwszym laserem o impulsach w zakresie nanosekundowym i drugim laserem o impulsach w zakresie piko- lub femtosekundowym; folia opakowaniowa
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
US9951009B2 (en) * 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
CN106432033B (zh) * 2016-10-21 2018-07-27 江苏阿尔法药业有限公司 一种无定形阿托伐他汀钙的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE123020T1 (de) * 1990-05-11 1995-06-15 American Cyanamid Co N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe.
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
KR100431038B1 (ko) 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
IN191236B (et) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina

Also Published As

Publication number Publication date
US6891047B2 (en) 2005-05-10
SI20425A (sl) 2001-06-30
TR200402543T4 (tr) 2004-12-21
US20040024046A1 (en) 2004-02-05
AU776854B2 (en) 2004-09-23
SK287032B6 (sk) 2009-10-07
PT1237864E (pt) 2004-11-30
WO2001042209A1 (en) 2001-06-14
HRP20020482A2 (en) 2004-08-31
KR100729689B1 (ko) 2007-06-18
EP1237864A1 (en) 2002-09-11
RU2247113C2 (ru) 2005-02-27
BG65719B1 (bg) 2009-08-31
EE200200293A (et) 2003-06-16
JP2003516388A (ja) 2003-05-13
ATE270661T1 (de) 2004-07-15
PL356184A1 (en) 2004-06-14
RS50307B (sr) 2009-09-08
CA2392025C (en) 2009-06-02
UA71041C2 (uk) 2004-11-15
US20020183527A1 (en) 2002-12-05
KR20020073137A (ko) 2002-09-19
CA2392025A1 (en) 2001-06-14
DE60012045T2 (de) 2005-07-07
EP1237864B1 (en) 2004-07-07
SK7832002A3 (en) 2002-11-06
DE60012045D1 (de) 2004-08-12
ES2223615T3 (es) 2005-03-01
BG106786A (en) 2003-05-30
CZ301627B6 (cs) 2010-05-05
YU36802A (sh) 2005-09-19
HRP20020482B1 (en) 2007-05-31
PL208226B1 (pl) 2011-04-29
US6613916B2 (en) 2003-09-02
JP5087193B2 (ja) 2012-11-28
AU1543801A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
EE200200293A (et) Meetod amorfse atorvastatiini valmistamiseks
MA27044A1 (fr) FORMES CRISTALLINES DE SEL DE CALCIUM(2 :1) D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO) CARBONYL]-1H-PYRROLE-1-HEPTANOiQUE (ATORVASTATINE)
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
GR3035859T3 (en) Novel process for the production of amorphous [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DK0848705T3 (da) Krystallinsk [R-(R*,R*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1- heptansyre-hemicalciumsalt (atorvastatin)
BG108518A (en) Crystalline forms vi and vii of atorvastatin calcium
NZ533935A (en) Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1)
IL173651A0 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
DE69616358D1 (de) Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin)
CA2522899A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
TH76289A (th) กระบวนการผลิตอะทอร์วาสเตตินแคลเซียมในรูปแบบอสัณฐาน

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20121205